The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Protease‐activated prodrugs: strategies, challenges, and future directions
Abstract
Proteases play critical roles in virtually all biological processes, including proliferation, cell death and survival, protein turnover, and migration. However, when dysregulated, these enzymes contribute to the progression of multiple diseases, with cancer, neurodegenerative disorders, inflammation, and blood disorders being the most prominent examples. For a long time, disease‐associated proteases have been used for the activation of various prodrugs due to their well‐characterized catalytic activity and ability to selectively cleave only those substrates that strictly correspond with their active site architecture. To date, versatile peptide sequences that are cleaved by proteases in a site‐specific manner have been utilized as bioactive linkers for the targeted delivery of multiple types of cargo, including fluorescent dyes, photosensitizers, cytotoxic drugs, antibiotics, and pro‐antibodies. This platform is highly adaptive, as multiple protease‐labile conjugates have already been developed, some of which are currently in clinical use for cancer treatment. In this review, recent advancements in the development of novel protease‐cleavable linkers for selective drug delivery are described. Moreover, the current limitations regarding the selectivity of linkers are discussed, and the future perspectives that rely on the application of unnatural amino acids for the development of highly selective peptide linkers are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Kayagaki, N., Stowe, I. B., Lee, B. L., O’Rourke, K., Anderson, K., Warming, S., Cuellar, T., Haley, B., Roose-Girma, M., Phung, Q. T., et al. (2015) · Nature · doi:10.1038/nature15541 · Cited by 3,686
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Rawlings, N. D., Barrett, A. J., Thomas, P. D., Huang, X., Bateman, A., & Finn, R. D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1134 · Cited by 1,749
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
Matrix metalloproteinases (MMPs) in health and disease: an overview
Malemud, C. (2006) · Frontiers in Bioscience · doi:10.2741/1915 · Cited by 705
Cathepsin B as a cancer target
Gondi, C. S., & Rao, J. S. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.740461 · Cited by 399
ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development
Walles, M., Connor, A., & Hainzl, D. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180118153502 · Cited by 45
Lysosomal Cathepsin A Plays a Significant Role in the Processing of Endogenous Bioactive Peptides
Timur, Z. K., Akyildiz Demir, S., & Seyrantepe, V. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00068 · Cited by 38
Cited by
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 842
Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)
Cooper, B. M., Iegre, J., O' Donovan, D. H., Ölwegård Halvarsson, M., & Spring, D. R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00556h · Cited by 414
Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Edupuganti, V. V. S. R., Tyndall, J. D. A., & Gamble, A. B. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210509001139 · Cited by 36
Deep learning guided design of protease substrates
Martin-Alonso, C., Alamdari, S., Samad, T. S., Yang, K. K., Bhatia, S. N., & Amini, A. P. (2026) · Nature Communications · doi:10.1038/s41467-025-67226-1 · Cited by 14
Metadata
- Authors
- Poreba, M.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2020-02-26
- Volume
- 287
- Issue
- 10
- Pages
- 1936-1969
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W3003913151
- Cited by
- 160
- References
- 10
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protease‐activated prodrugs: strategies, challenges, and future directions. https://app.cochat.ai/papers/10.1111/febs.15227
- The paper
- Poreba, M. (2020). Protease‐activated prodrugs: strategies, challenges, and future directions. The FEBS Journal. https://doi.org/10.1111/febs.15227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.